A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Public ClinicalTrials.gov record NCT05646706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. In the first part of the study, participants will get one injection once a week until they reach the planned dose. The second part of the study, which might last a couple of months, is a transition period, where participant will get three injections, taken right after each other, once a week. The duration of the study intervention (trial product and lifestyle intervention) will be 72 weeks followed by a 9-week follow-up period without study interventions.
Study identification
- NCT ID
- NCT05646706
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,407 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2023 (Actual)
- Primary completion
- Oct 30, 2024 (Actual)
- Completion
- Nov 26, 2024 (Actual)
- Last update posted
- Apr 23, 2026
2023 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| Chambliss Clinical Trials, LLC | Montgomery | Alabama | 36106 | — |
| Healthscan Clinical Trials,LLC. | Montgomery | Alabama | 36106 | — |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Jacksonville Ctr For Clin Res | Jacksonville | Florida | 32216 | — |
| Florida Inst For Clin Res LLC | Orlando | Florida | 32825 | — |
| Florida Institute For Clinical Research LLC | Orlando | Florida | 32825 | — |
| East West Med Res Inst | Honolulu | Hawaii | 96814 | — |
| Midwest Inst For Clin Res | Indianapolis | Indiana | 46260 | — |
| AMC Community Endocrinology | Albany | New York | 12203 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Medical University Of South Carolina | Charleston | South Carolina | 29425 | — |
| Amarillo Med Spec LLP | Amarillo | Texas | 79106 | — |
| Elligo Clin Res Centre | Austin | Texas | 78704 | — |
| Velocity Clin Res, Dallas | Dallas | Texas | 75230 | — |
| UT Southwestern Medical Center-CRU | Dallas | Texas | 75390 | — |
| DCOL Ctr for Clin Res | Longview | Texas | 75605 | — |
| Sugar Lakes Family Practice PA | Sugar Land | Texas | 77479 | — |
| National Clin Res Inc. | Richmond | Virginia | 23294 | — |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05646706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05646706 live on ClinicalTrials.gov.